Corbus Pharmaceuticals Holdings, Inc. (CRBP) stock
CRBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.75−0.26 (-8.80%)
Close on Nov 18, 2026Market cap $53.09MP/E –Yield –
Corbus Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Corbus Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$106.88M. For fiscal 2025 it was -$85.31M. The highest annual figure on record is -$557.28K in fiscal 2013.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$85.31M | – |
| FY2024 | Dec 31, 2024 | -$48.72M | – |
| FY2023 | Dec 31, 2023 | -$45.08M | – |
| FY2022 | Dec 31, 2022 | -$39.84M | – |
| FY2021 | Dec 31, 2021 | -$55.99M | – |
| FY2020 | Dec 31, 2020 | -$122.81M | – |
| FY2019 | Dec 31, 2019 | -$77.10M | – |
| FY2018 | Dec 31, 2018 | -$56.75M | – |
| FY2017 | Dec 31, 2017 | -$32.56M | – |
| FY2016 | Dec 31, 2016 | -$19.99M | – |
| FY2015 | Dec 31, 2015 | -$8.85M | – |
| FY2014 | Dec 31, 2014 | -$2.65M | – |
| FY2013 | Dec 31, 2013 | -$557.28K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$36.19M | – |
| Q1 FY2026 | Mar 31, 2026 | -$24.30M | – |
| Q4 FY2025 | Dec 31, 2025 | -$21.97M | – |
| Q3 FY2025 | Sep 30, 2025 | -$24.42M | – |
| Q2 FY2025 | Jun 30, 2025 | -$19.15M | – |
| Q1 FY2025 | Mar 31, 2025 | -$19.78M | – |
| Q4 FY2024 | Dec 31, 2024 | -$12.61M | – |
| Q3 FY2024 | Sep 30, 2024 | -$15.51M | – |
| Q2 FY2024 | Jun 30, 2024 | -$10.99M | – |
| Q1 FY2024 | Mar 31, 2024 | -$9.62M | – |
| Q4 FY2023 | Dec 31, 2023 | -$10.10M | – |
| Q3 FY2023 | Sep 30, 2023 | -$9.49M | – |
| Q2 FY2023 | Jun 30, 2023 | -$8.19M | – |
| Q1 FY2023 | Mar 31, 2023 | -$17.30M | – |
| Q4 FY2022 | Dec 31, 2022 | -$10.80M | – |
| Q3 FY2022 | Sep 30, 2022 | -$8.18M | – |
| Q2 FY2022 | Jun 30, 2022 | -$12.34M | – |
| Q1 FY2022 | Mar 31, 2022 | -$8.52M | – |
| Q4 FY2021 | Dec 31, 2021 | -$10.00M | – |
| Q3 FY2021 | Sep 30, 2021 | -$13.88M | – |
| Q2 FY2021 | Jun 30, 2021 | -$16.70M | – |
| Q1 FY2021 | Mar 31, 2021 | -$15.41M | – |
| Q4 FY2020 | Dec 31, 2020 | -$20.81M | – |
| Q3 FY2020 | Sep 30, 2020 | -$33.97M | – |
| Q2 FY2020 | Jun 30, 2020 | -$38.14M | -2336.6% |
| Q1 FY2020 | Mar 31, 2020 | -$29.89M | – |
| Q4 FY2019 | Dec 31, 2019 | -$27.19M | – |
| Q3 FY2019 | Sep 30, 2019 | -$25.10M | – |
| Q2 FY2019 | Jun 30, 2019 | $1.71M | – |
| Q1 FY2019 | Mar 31, 2019 | -$26.52M | – |
| Q4 FY2018 | Dec 31, 2018 | -$17.59M | – |
| Q3 FY2018 | Sep 30, 2018 | -$14.90M | – |
| Q2 FY2018 | Jun 30, 2018 | -$12.39M | – |
| Q1 FY2018 | Mar 31, 2018 | -$11.86M | – |
| Q4 FY2017 | Dec 31, 2017 | -$10.86M | – |
| Q3 FY2017 | Sep 30, 2017 | -$6.96M | – |
| Q2 FY2017 | Jun 30, 2017 | -$7.29M | – |
| Q1 FY2017 | Mar 31, 2017 | -$7.45M | – |
| Q4 FY2016 | Dec 31, 2016 | -$7.57M | – |
| Q3 FY2016 | Sep 30, 2016 | -$5.33M | – |
See a number that looks wrong?